Ignite Creation Date:
2025-12-24 @ 10:31 PM
Ignite Modification Date:
2026-01-01 @ 12:44 PM
Study NCT ID:
NCT00035035
Status:
COMPLETED
Last Update Posted:
2006-07-19
First Post:
2002-05-02
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.
Sponsor:
Eli Lilly and Company
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
None
Start Date Type:
None
Primary Completion Date:
None
Primary Completion Date Type:
None
Completion Date:
None
Completion Date Type:
None
First Submit Date:
2002-05-02
First Submit QC Date:
None
Study First Post Date:
2002-05-03
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2006-07-18
Last Update Post Date:
2006-07-19
Last Update Post Date Type:
ESTIMATED